BioSpace News Archive

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1 (DM1).

ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test.

JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes, a chronic autoimmune condition, and the role screening could play in the early detection of this disease.

Dynocardia, developer of ViTrack, the first-of-its-kind non-invasive, wearable blood pressure and heart monitor, and NYC Health + Hospitals, the nation’s largest safety net health system, are partnering on a study of hypertensive diseases of pregnancy.

Avantor, Inc. announced that Michael Stubblefield, President and CEO, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston on Tuesday, March 5, 2024, at approximately 10:30 a.m. Eastern Standard Time.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).

Astria Therapeutics, Inc. today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

NextPoint Therapeutics announced today that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.

Janux Therapeutics, Inc. today announced it will host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February 26th, 2024, at 4:30PM ET.

National Resilience, Inc. today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network.